Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Long-Term Investments: 2017-2025

Historic Long-Term Investments for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2025 value amounting to $24.7 million.

  • Denali Therapeutics' Long-Term Investments fell 94.45% to $24.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year decrease of 94.45%. This contributed to the annual value of $359.4 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Long-Term Investments is $24.7 million, which was down 68.52% from $78.5 million recorded in Q2 2025.
  • Denali Therapeutics' Long-Term Investments' 5-year high stood at $490.7 million during Q1 2024, with a 5-year trough of $7.9 million in Q3 2023.
  • Moreover, its 3-year median value for Long-Term Investments was $297.6 million (2024), whereas its average is $261.7 million.
  • As far as peak fluctuations go, Denali Therapeutics' Long-Term Investments spiked by 5,535.21% in 2024, and later slumped by 94.45% in 2025.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Long-Term Investments stood at $425.4 million in 2021, then climbed by 1.84% to $94.2 million in 2022, then reached $7.9 million in 2023, then skyrocketed by 5,535.21% to $359.4 million in 2024, then tumbled by 94.45% to $24.7 million in 2025.
  • Its Long-Term Investments was $24.7 million in Q3 2025, compared to $78.5 million in Q2 2025 and $235.8 million in Q1 2025.